Vyant Bio (OTCMKTS:VYNT) Trading 7.8% Higher – Still a Buy?

Shares of Vyant Bio, Inc. (OTCMKTS:VYNTGet Free Report) shot up 7.8% during mid-day trading on Thursday . The company traded as high as $0.20 and last traded at $0.19. 19,100 shares traded hands during trading, a decline of 88% from the average session volume of 161,822 shares. The stock had previously closed at $0.18.

Vyant Bio Trading Up 7.8%

The stock’s 50-day moving average price is $0.19 and its 200-day moving average price is $0.19. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.86 and a current ratio of 2.86.

Vyant Bio Company Profile

(Get Free Report)

Vyant Bio, Inc, a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD).

Featured Articles

Receive News & Ratings for Vyant Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vyant Bio and related companies with MarketBeat.com's FREE daily email newsletter.